Article

Generic Version of Vagifem Launched

Author(s):

Yuvafem delivers the same low dose of vaginal estrogen in a pre-loaded, single-use, disposable applicator.

Amneal has launched the first-to-market generic version of Vagifem, being sold as Yuvafem. The 10-mcg estradiol vaginal inserts were shipped to distributors and wholesalers beginning on Oct. 17, 2016.

Yuvafem delivers the same low dose of vaginal estrogen in a pre-loaded, single-use, disposable applicator. It is packaged in 8- and 18-count size quantities for new and maintenance prescriptions.

The product is designed to treat atrophic vaginitis as a result of menopause. The most common adverse effects associated with Yuvafem are upper respiratory tract infection, headache, abdominal pain, back pain, genital pruritus, moniliasis, vulvovaginal mycotic infection, and diarrhea.

Amneal successfully completed a clinical endpoint study required by the FDA prior to Yuvafem’s ANDA approval.

“Patients and healthcare providers have been eager to see a generic for this unique dosage form in order to benefit from the cost savings such multi-source products can deliver,” said Chirag Patel, Amneal co-CEO and chairman, in a press release. “As a company, we are not only pleased to be able to offer a potentially more affordable option in this therapeutic category, but to add to our rapidly growing portfolio of oral contraceptives and hormone replacement therapies in such a significant way.”

The product should not be used in women who have certain conditions, including undiagnosed genital bleeding, known or suspected history of breast cancer, and liver impairment. Some women may also have an increased risk of stroke as a result of using an estrogen-alone therapy.

Related Videos
Image Credit: © Birdland - stock.adobe.com
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © Andrey Popov - stock.adobe.com